Elevated serum fibroblast growth factor 21 levels correlate with immune recovery but not mitochondrial dysfunction in HIV infection

AIDS Research and Therapy

Volumn 10, Issue 1, 2013, Pages

  Payne, Brendan A I ^a,b   Price, David A ^b   Chinnery, Patrick F ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Anti retroviral therapy; Fibroblast growth factor 21; Highly active; HIV; Mitochondria

Indexed keywords

ABACAVIR; ATAZANAVIR; CYTOCHROME C OXIDASE; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FIBROBLAST GROWTH FACTOR 21; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MALE; MITOCHONDRIAL TOXICITY; MUSCLE BIOPSY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKELETAL MUSCLE;

EID: 84887708414     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-10-27     Document Type: Article

References (25)

1. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990, 322:1098-1105. 10.1056/NEJM199004193221602, 2320079.
2. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991, 337:508-510. 10.1016/0140-6736(91)91294-5, 1671889.
3. Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S, Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. Aids 2001, 15:1801-1809. 10.1097/00002030-200109280-00009, 11579242.
4. Zaera MG, Miro O, Pedrol E, Soler A, Picon M, Cardellach F, Casademont J, Nunes V. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. Aids 2001, 15:1643-1651. 10.1097/00002030-200109070-00006, 11546938.
5. van der Valk M, Casula M, Weverlingz GJ, van Kuijk K, van Eck-Smit B, Hulsebosch HJ, Nieuwkerk P, van Eeden A, Brinkman K, Lange J, et al. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther 2004, 9:385-393.
6. Walker UA, Bauerle J, Laguno M, Murillas J, Mauss S, Schmutz G, Setzer B, Miquel R, Gatell JM, Mallolas J. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004, 39:311-317. 10.1002/hep.20074, 14767983.
7. Miro O, Lopez S, Pedrol E, Rodriguez-Santiago B, Martinez E, Soler A, Milinkovic A, Casademont J, Nunes V, Gatell JM, Cardellach F. Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy. Antivir Ther 2003, 8:333-338.
8. Payne BA, Wilson IJ, Hateley CA, Horvath R, Santibanez-Koref M, Samuels DC, Price DA, Chinnery PF. Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations. Nat Genet 2011, 43:806-810. 10.1038/ng.863, 3223397, 21706004.
9. Chiappini F, Teicher E, Saffroy R, Pham P, Falissard B, Barrier A, Chevalier S, Debuire B, Vittecoq D, Lemoine A. Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients. Lab Invest 2004, 84:908-914. 10.1038/labinvest.3700113, 15122308.
10. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV, Montaner JS. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002, 346:811-820. 10.1056/NEJMoa012035, 11893792.
11. Montaner JS, Cote HC, Harris M, Hogg RS, Yip B, Chan JW, Harrigan PR, O'Shaughnessy MV. Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. J Acquir Immune Defic Syndr 2003, 34(Suppl 1):S85-S90.
12. Cherry CL, Gahan ME, McArthur JC, Lewin SR, Hoy JF, Wesselingh SL. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 2002, 30:271-277.
13. Hoschele D. Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity. Toxicol In Vitro 2006, 20:535-546. 10.1016/j.tiv.2005.11.007, 16406476.
14. Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab Invest 2001, 81:1537-1544. 10.1038/labinvest.3780367, 11706061.
15. Hammond E, Nolan D, James I, Metcalf C, Mallal S. Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy. Aids 2004, 18:815-817. 10.1097/00002030-200403260-00015, 15075519.
16. Lim SE, Copeland WC. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 2001, 276:23616-23623. 10.1074/jbc.M101114200, 11319228.
17. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002, 46:716-723. 10.1128/AAC.46.3.716-723.2002, 127499, 11850253.
18. Suomalainen A, Elo JM, Pietilainen KH, Hakonen AH, Sevastianova K, Korpela M, Isohanni P, Marjavaara SK, Tyni T, Kiuru-Enari S, et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol 2011, 10:806-818. 10.1016/S1474-4422(11)70155-7, 21820356.
19. Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Noblitt TW, Otto KA, Reifel-Miller A, Kharitonenkov A. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J Cell Physiol 2007, 210:1-6. 10.1002/jcp.20847, 17063460.
20. Affandi JS, Price P, Imran D, Yunihastuti E, Djauzi S, Cherry CL. Can we predict neuropathy risk before stavudine prescription in a resource-limited setting?. AIDS Res Hum Retroviruses 2008, 24:1281-1284. 10.1089/aid.2008.0045, 18834321.
21. Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W, Tang Y, Liu H, Boden G. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008, 116:65-68. 10.1055/s-2007-985148, 17926232.
22. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, Badman MK, Martinez-Chantar ML, Maratos-Flier E. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010, 139:456-463. 10.1053/j.gastro.2010.04.054, 20451522.
23. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, Xu A. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 57:1246-1253. 10.2337/db07-1476, 18252893.
24. Domingo P, Gallego-Escuredo JM, Domingo JC, Gutierrez Mdel M, Mateo MG, Fernandez I, Vidal F, Giralt M, Villarroya F. Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. AIDS 2010, 24:2629-2637. 10.1097/QAD.0b013e3283400088, 20935553.
25. Friis-Moller N, Sabin CA, Weber R, D'Arminio Monforte A, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993-2003.